United States: Key Implications Of The 21st Century Cures Act For Medical Devices

Key Points

  • The 21st Century Cures Act ("Cures" or the "Act") significantly impacts FDA's review and approval of medical devices, and how medical devices are covered and paid for.
  • These new authorities give FDA greater flexibility in regulating medical devices, but their ultimate impact will depend on how they are implemented by the agency under a new administration.
  • Because the Cures device provisions are more heavily focused on premarket review, expect additional consideration of postmarket device surveillance in next year's FDA reauthorization process.

This week, the U.S. Senate passed the comprehensive legislative package referred to as the 21st Century Cures Act. The Senate's passage follows an overwhelming passage by the House of Representatives last week, and the President is expected to sign the legislation into law on December 13th.

The legislation, which follows more than two years of discussion, contains a vast array of changes for the health care system and authorizes, over 10 years, $4.8 billion in funding for research and $1 billion to fight the opioid crisis; it provides an additional $500 million to FDA, although Congress has appropriated only the first year of funding so far. In addition to making significant changes to FDA regulation of medical products, the legislation addresses National Institutes of Health (NIH) research, opioids, mental health, hospitals and medical countermeasures. This client alert focuses on the key Cures provisions affecting medical devices and diagnostics.

Key FDA Regulatory Reforms Related to Devices

Breakthrough Devices

Cures creates a priority review program for "breakthrough" devices that is modeled on the breakthrough pathway for drugs.1 The provision as enacted is available to qualifying devices that will go through the premarket approval (PMA), de novo, or 510(k) pathways. The breakthrough pathway criteria are somewhat broader than the criteria for FDA's existing Expedited Access Pathway. To qualify, a device must demonstrate that it provides for more effective treatment or diagnosis of a life-threatening or irreversibly debilitating human disease or condition, and meets one of the following criteria: (1) it represents a breakthrough technology; (2) it has no approved or cleared alternative; (3) it offers significant advantages over existing approved or cleared alternatives, including "the potential, compared to existing approved alternatives, to reduce or eliminate the need for hospitalization, improve patient quality of life, facilitate patients' ability to manage their own care . . . , or establish long-term clinical efficiencies"; or (4) its availability is in the best interest of patients.

FDA will have 60 days to accept or deny a sponsor's request for designation as a breakthrough device. FDA's denial of an application constitutes a "significant decision," which a sponsor may appeal. To facilitate expedient review, FDA must assign a team of staff, adopt an efficient dispute resolution process, provide for interactive and timely communication with the sponsor, collaborate with the sponsor on clinical trial design, and expedite review of manufacturing and quality systems compliance. FDA must publish guidance on implementation of this section within one year of enactment of the Act.

Medical Device Software

Cures clarifies which types of digital health applications constitute medical devices.2 Although the Cures medical software provisions mirror FDA's current approach in many respects, they appear to depart from FDA policy in several ways. Akin Gump plans to issue a separate alert specifically addressing the Medical Device Software provision.

Under Cures, the following five functions or uses, subject to certain conditions, will not be considered medical devices:

  • Administrative Support: administrative support of a health care facility, including the processing and maintenance of financial records, claims, billing information, information about patient populations, business analytics, practice and inventory management, analysis of historical claims data to predict future utilization or cost-effectiveness, and population health management
  • Healthy Lifestyle/Wellness: maintaining or encouraging a healthy lifestyle, provided the function is unrelated to the diagnosis, cure, mitigation, prevention or treatment of a disease or condition
  • Electronic Patient Records: use as electronic patient records, including patient-provided information, to the extent that the records are intended to transfer, store, convert formats, or display the equivalent of a paper medical chart so long as the records were created, stored, transferred or reviewed by health care professionals or individuals working under their supervision; are part of health information technology certified by the Office of the National Coordinator; and are not intended to interpret or analyze patient records, including medical image data, for the purpose of the diagnosis, cure, mitigation, prevention, or treatment of a disease or condition
  • Transfer/Storage of Medical Device Data: transferring, storing, converting formats, or displaying clinical laboratory test or other device data and results, findings by a health care professional with respect to such data and results, general information about the findings, and general background information about the test or other device, unless the function is intended to interpret or analyze clinical laboratory tests or other device data, results, and findings (note that this provision is not perfectly aligned with FDA's definition of Medical Device Data Systems)
  • Clinical Support: (1) displaying, analyzing or printing medical information; (2) supporting or providing recommendations to a health care professional about prevention, diagnosis, or treatment of a disease or condition; and (3) enabling such health care professional to independently review the basis for such recommendations, so long as the function is not intended to acquire, process, or analyze a medical image or signal from an in vitro diagnostic device or a pattern or signal from a signal acquisition system.

For certain of the exempted functions, however, FDA may apply device requirements if the agency determines through notice and comment rulemaking that it is reasonably likely to have serious adverse health consequences.

FDA must publish a report within two years of enactment, and then every two years thereafter, that examines information about risks and benefits to health associated with these software functions, taking into account input from industry stakeholders.

Regulation of Accessories

The Cures software provisions also address medical device accessories. Under the Act, accessories are to be classified by FDA based on their own intended use and not on the intended use of any devices with which they are intended to be used (which often results in a higher risk classification for the accessory).3 This has relatively recently been FDA's position (and has been proposed in draft guidance), but it is now codified in law.

Cleaning Instructions and Validation Requirements for Reusable Devices

Cures requires FDA to publish a list of reusable device types for which 510(k) clearance will require validated instructions for use and validation data regarding cleaning, disinfection, and sterilization.4 Any 510(k) submissions for such device types made after the date that FDA publishes its list must include these validated instructions for use and validation data. FDA must revise the list as it deems appropriate by issuing a notice in the Federal Register.

This provision stems, in large part, from recent reports of infections spreading among patients from the use of reusable duodenoscopes.

Humanitarian Device Exemption

This section expands the humanitarian device exemption (HDE) to devices that treat or diagnose a disease or condition that affects no more than 8,000 individuals in the United States per year, an increase from the current limit of 4,000 individuals. FDA is also required to issue guidance on the "probable benefit" criterion for granting an HDE.5

Least Burdensome Device Review

FDA must provide training to reviewers regarding the meaning and implementation of the "least burdensome" principles of the Food, Drug, and Cosmetic Act (FDCA), which require FDA to consider the least burdensome means of evaluating device effectiveness or substantial equivalence for purposes of premarket review.6 Within 18 months of enactment, the ombudsman must audit the implementation of these requirements. FDA must consider the least burdensome means necessary to demonstrate a reasonable assurance of safety and effectiveness when it requests additional information regarding a PMA application, including evaluation of postmarket information.

IRB Flexibility

This section removes the statutory reference to a sponsor of a medical device trial using a local institutional review board (IRB).7 This change allows for the use of centralized IRB models for multicenter trials.

Recognition of Standards

This section establishes a process for submission, review and recognition of standards established by nationally or internationally recognized standard organizations for purposes of facilitating medical device review.8

Certain Class I and Class II Devices

Within 120 days of enactment, and then at least once every five years, FDA must publish a list of the types of Class I devices that are newly exempted from 510(k) in the Federal Register.9 FDA must do the same for Class II devices within 90 days of enactment, and then at least once every five years.

Classification Panels

This provision aims to improve medical device classification panels by ensuring adequate expertise among panel members, allowing a sponsor to offer recommendations on the required expertise and permitting a sponsor representative to address the panel.10

CLIA Waiver Improvements

FDA must update its 2008 guidance on determining when a test is eligible for a Clinical Laboratory Improvement Amendments of 1988 (CLIA) waiver by allowing for demonstration of accuracy through comparable performance between a waived and a moderately-complex user.

Other FDA-Related Provisions Affecting the Device Industry

Other FDA-related Cures provisions are not solely directed at medical devices, but hold implications for device makers.

Combination Products

The Act reforms the process for reviews of combination products, requiring FDA to issue guidance on a structured review process.11 The provision seeks to address the concern that FDA treats the presence of any chemical action as rendering the "primary" mode of action (PMOA) to that of a drug or biologic.12 In determining a product's PMOA, FDA categorizes combination products based on the statutory definition that a product is not a device if it "achieve[s] its primary intended purposes through chemical action within or on the body of man." Sponsors can request a substantive rationale that references scientific evidence for the agency's determination of the PMOA. Although this provision clarifies that FDA cannot classify combination products with merely "any" chemical action as having the PMOA of a drug or biologic, the degree of chemical action that may be present for a product to have a device PMOA may still be difficult to discern.

In addition:

  • Sponsors may meet with the review team and receive FDA's feedback on proposed studies to establish the relevance of any chemical action.
  • When reviewing a combination product that contains a component that has already been approved or cleared, FDA must take into account the prior determination of safety and effectiveness and may request only data or information that is necessary to make a premarket review decision on the product as a whole, such as data on the incremental risks and benefits posed by the combination product.
  • Under the Act, certain device-led combination products shall be considered, for purposes of determining eligibility for drug marketing exclusivity, to have been submitted as a "505(b)(2)" application (in reference to the FDCA provision)—a drug application that relies, in part, on studies not conducted by the applicant. This provision may make it easier for combination products to qualify for marketing exclusivity, but it also may allow a sponsor of a drug under exclusivity to "block" device-led combination products that use that drug.
  • FDA is required to publish a list of proposed combination product types that could employ less burdensome Good Manufacturing Practices (GMP) requirements than would apply under FDA's current streamlined GMP regulations.

Off-Label Communication of Economic Information

The Act amends the FDCA's prohibition on misbranding to expand the scope of off-label information that manufacturers can share with payors.13 Specifically, the provision broadens an existing safe harbor for sharing "health care economic information" with additional types of payor entities in addition to formulary committees. Although the expanded language refers to off-label information about drugs and biologics, the same principles might provide a road map in the event that FDA—or Congress in next year's FDA user fee reauthorization—clarifies the parameters for the sharing of health care economic information about off-label uses of devices.

Real World Evidence

Cures requires FDA to evaluate the use of "real world evidence" to help support approval of a new indication for a previously approved drug and help support or satisfy post-approval study requirements.14 This provision does not apply to medical devices, although the draft commitment letter for the Medical Device User Fee Agreement reauthorization package contemplates a similar initiative for devices. Under the commitment letter, FDA will apply user fee funding to support a National Evaluation System for health Technology (NEST), which will establish programs to assess the feasibility of applying real world evidence for expanded indications for use, new clearances and approvals, and improved malfunction reporting.

Precision Medicine Initiative and Cancer Moonshot Efforts

The Act codifies congressional support for the Obama administration's goal to cure cancer by providing funding and encouraging the Secretary HHS to support its efforts. The Act allocates $1.4 billion over the next decade to fund NIH to support the Precision Medicine Initiative, which is President Obama's effort to advance development of individualized patient care through research, technology, and policy-making. It also provides $1.8 billion in funding to the NIH for fiscal years 2017 to 2021 to support the Cancer Moonshot, the Administration's mission to end cancer led by Vice President Biden. This funding is intended to support cancer research through development of combination therapies, cancer vaccines, more sensitive diagnostic tests, immunotherapies, and research that has the potential to transform the scientific field, that has inherently higher risk, and seeks to address major challenges related to cancer.

In addition, the Act empowers the HHS Secretary to carry out the Precision Medicine Initiative, which may include developing a network of scientists, developing new approaches to address regulatory and scientific issues, applying genomic technologies, and gathering information to better understand health and disease.

Regenerative Medicine Provisions

A relatively late addition to the Cures legislation was a set of provisions on regenerative medicine.15 These provisions direct FDA to consider certain regenerative medicine therapies (including combination products) under existing expedited approval pathways/processes. FDA must also issue guidance within one year of enactment to clarify how it will evaluate devices used in the recovery, isolation or delivery of regenerative advanced therapies. The guidance must address:

  • how FDA will streamline regulatory requirements for combination device and cell or tissue products
  • which intended uses or attributes would make a device used with a regenerative therapy a Class III device
  • when the FDA requires an intended use to be specific to only one particular type of cell
  • application of the least burdensome approach to demonstrate how a device may be used with more than one cell type.

Coverage and Payment Provisions

Cures also includes a number of Medicare and Medicaid-related provisions, many of which have implications for coverage and payment for medical devices and diagnostics.

Increased Transparency for Medicare Local Coverage Determinations (LCDs)

LCDs are decisions made by Medicare Administrative Contractors (MACs) to cover (or limit coverage for) a particular item or service, such as a device, within the MAC's assigned geographic region.16 Beginning six months after enactment, MACs must post certain information on their websites at least 45 days prior to the effective date of a final LCD, including a summary of the evidence considered and an explanation of the rationale supporting the LCD. Although current Centers for Medicare & Medicaid Services (CMS) policy requires MACs to provide notice and opportunity for stakeholder comment on draft LCDs, the Cures provision enhances these existing procedural protections.

Medicare Pharmaceutical and Technology Ombudsman

Cures establishes a "pharmaceutical and technology ombudsman" within CMS to handle complaints, grievances, and other requests from pharmaceutical and medical device manufacturers seeking Medicare coverage for their products.17 The ombudsman would specifically be charged with addressing coverage, coding and payment, providing manufacturers with a potential new avenue to work with the agency to resolve access barriers arising from these issues.

Medicare Part B Payment for Home Infusion Therapy and Durable Medical Equipment (DME) Infusion Drugs

Cures establishes a new Medicare benefit and payment system for "home infusion therapy," which encompasses the nursing, training and education, and remote monitoring services associated with administering certain infusion drugs in a patient's home.18 Pharmacies and other providers furnishing these services would receive a single payment for each day of infusion administration. The Medicare reimbursement formula for DME infusion drugs (i.e., drugs that are infused through DME-covered infusion pumps) is reduced from 95 percent of Average Wholesale Price to 106 percent of Average Sales Price, bringing payment for such drugs in line with other types of Part B-covered drugs.

Expansion of Telehealth Services under Medicare

The Act includes a "sense of the Congress" that telehealth services be expanded under the Medicare program.19 Toward this end, CMS must report certain relevant information to Congress, including the Medicare patient populations that may benefit from increased access to telehealth and any barriers that might prevent its expansion. It also calls for a Medicare Payment Advisory Commission report to Congress on telehealth.

Delay in Implementation of Payment Cuts to the Medicare DME Fee Schedule

Cures delays by six months the expansion of DME competitive bidding to rural geographic areas that were not originally subject to competitive bidding.20 Full implementation of these cuts, which have already been delayed by Congress this year, will take place on January 1, 2017, instead of July 1, 2016. The extension of the current transition period for these rate reductions comes in response to industry concerns about the impact on patient access, particularly in rural areas. HHS is also directed to study the impact of the cuts on the number of suppliers and patient access.

Medicaid Reimbursement for DME

Current law limits federal payments to state Medicaid programs based on Medicare payment rates for DME beginning in 2019.21 Cures applies Medicare rates to Medicaid one year earlier, in 2018.

Sunshine Act Changes Omitted

The draft version of the Cures legislation released after Thanksgiving, as well as the 2015 House-passed bill, contained a provision to exempt certain transfers of value to physicians and other covered recipients from disclosure under the Sunshine Act, including textbooks, medical journal reprints, and honoraria and other costs associated with presenting and attending Continuing Medical Education (CME) that does not promote a specific product. This provision was removed from the final Cures legislation. As a result, such payments from device and drug manufacturers must continue to be disclosed to CMS' Open Payments system, except for industry-sponsored CME, which remains excluded at CMS' discretion.


1 H.R. 34, 114th Cong. § 3051 (2016).

2 H.R. 34, 114th Cong. § 3060 (2016).

3 H.R. 34, 114th Cong. § 3060(c) (2016).

4 H.R. 34, 114th Cong. § 3059 (2016).

5 H.R. 34, 114th Cong. § 3052 (2016).

6 H.R. 34, 114th Cong. § 3058 (2016).

7 H.R. 34, 114th Cong. § 3056 (2016).

8 H.R. 34, 114th Cong. § 3053 (2016).

9 H.R. 34, 114th Cong. § 3054 (2016).

10 H.R. 34, 114th Cong. § 3055 (2016).

11 H.R. 34, 114th Cong. § 3038 (2016).

12 Prevor v. FDA, 895 F. Supp. 2d 90, 95 (D.D.C. 2012); Prevor v. FDA, 67 F. Supp. 3d 125, 135 (D.D.C. 2014).

14 H.R. 34, 114th Cong. § 3022 (2016).

15 H.R. 34, 114th Cong. §§ 3033–3036 (2016).

16 H.R. 34, 114th Cong. § 4009 (2016).

17 H.R. 34, 114th Cong. § 4010 (2016).

18 H.R. 34, 114th Cong. §§ 5004; 5012 (2016).

19 H.R. 34, 114th Cong. § 4012 (2016).

20 H.R. 34, 114th Cong. § 16007 (2016).

21 H.R. 34, 114th Cong. § 5002 (2016).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.